Evidence map›Paper›PMID 28647165›Full record

ReviewVaccine2019

Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.

Sami L Gottlieb, Birgitte Giersing, Marie-Claude Boily, Harrell Chesson, Katharine J Looker, Joshua Schiffer, Ian Spicknall, Raymond Hutubessy, Nathalie Broutet, WHO HSV Vaccine Impact Modelling Meeting Working Group

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sami L GottliebWorld Health Organization (WHO), Geneva, Switzerland. Electronic address: gottliebs@who.int.
Birgitte GiersingWorld Health Organization (WHO), Geneva, Switzerland.
Marie-Claude BoilyImperial College, London, UK.
Harrell ChessonCenters for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Katharine J LookerUniversity of Bristol, UK.
Joshua SchifferUniversity of Washington, Seattle, WA, USA.
Ian SpicknallCenters for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Raymond HutubessyWorld Health Organization (WHO), Geneva, Switzerland.
Nathalie BroutetWorld Health Organization (WHO), Geneva, Switzerland.
WHO HSV Vaccine Impact Modelling Meeting Working Group

Funding

THE PERINATAL COMPLICATIONS OF ASYMPTOMATIC GENITAL HERPES SIMPLEX VIRUSP01AI030731 · NIAID · UNIVERSITY OF WASHINGTON · PI ZHU, JIA · 1991 to 2017
$34.3M
Medical Research Council MR/R015600/1NIAID NIH HHS P01 AI030731World Health Organization 001
6 · The paper itself

Abstract

Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.

Indexed as

Herpes GenitalisHerpes SimplexHerpes Simplex Virus VaccinesHerpesvirus 1, HumanHerpesvirus 2, HumanHumansWorld Health OrganizationHerpes Simplex Virus VaccinesHerpes simplex virusHSV vaccinesModellingSexually transmitted infections

Identifiers

PMID28647165
PMCPMC10599163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.